Over-expression of
P-glycoprotein (Pgp+) has been related to resistance to classical
Topo II inhibitors used in the treatment of AML and is common in patients with poor-prognosis, such as those with secondary AML (sAML). Since clinical trials with
amonafide, a unique
ATP-independent
Topo II inhibitor, in combination with
cytarabine, have shown significant efficacy for
remission induction in patients with sAML, we compared the cytotoxic effect of
amonafide (
amonafide l-
malate,
Xanafide) to the classical
Topo II inhibitors (
daunorubicin,
doxorubicin,
idarubicin,
etoposide, and
mitoxantrone) in K562
leukemia cells and in the MDR subline, K562/DOX. Pgp expression was found to be approximately 6.5-fold greater in K562/DOX and causes the rapid efflux of these drugs from the
leukemia cell. As a consequence, the LC(50) values for the classical
Topo II inhibitor drugs tested were each increased up to 3 log units. A similar result was also observed in murine P388 and P388/ADR
leukemia cells. Addition of
cyclosporin A reversed K562/DOX resistance for the classical
Topo II inhibitors, decreasing their LC(50) values to the levels observed with wild type cells but had no effect on
amonafide potency in Pgp+ or wild type cells. Further examination of
amonafide in bidirectional Caco-2 and MDR1-MDCK models confirmed that
amonafide is neither a substrate nor inhibitor of Pgp. These observations suggest that
amonafide is a promising therapeutic candidate directed toward bypassing this common mechanism of drug resistance encountered in the treatment of patients with AML, and possibly in other resistant
hematological malignancies as well.